PharmTech Weekly Roundup–July 10, 2026

This week, regulators, dealmakers, and manufacturers converged on the same demand: greater accountability and resilience across drug development and manufacturing. From phased and accelerated regulatory reviews, to enforcement on artificial intelligence (AI)-assisted documentation, to acquisitions built to close capability gaps, the pressure is on to build systems that are faster, better controlled, and more transparent.

In regulatory news this week, the European Medicines Agency’s (EMA’s) phased review of daraxonrasib for metastatic pancreatic cancer previews how legislative reform for pharmaceuticals in the European Union may help regulators assess quality and clinical data in stages, compressing timelines without lowering the evidentiary bar.

The FDA’s accelerated approval of Trutakna, the first dual BAFF and APRIL inhibitor for IgA nephropathy, highlights the pairing of self-administered specialty biologics with near-term confirmatory data requirements.

In business news, Novartis’s acquisition of Myricx Bio, worth up to $1.5 billion, is the next in a string of deals showing that payload and linker chemistry, not just antibody targeting, are driving competitive differentiation in next-generation ADCs.

And finally, Teva and Polpharma Biologics’ licensing deal for an ocrelizumab biosimilar expands access to specialized biologics in the multiple sclerosis market.

Industry experts took a look at a variety of topics this week on PharmTech.com.

In an article, authors Pandey and Borshchenko explained how the FDA’s warning letter to Purolea Cosmetics Lab shows that AI-assisted drafting of good manufacturing practice (GMP) documents still requires quality-unit review, controlled source material, and process validation performed by experts.

USP’s Gabriela Grasa Mannino explained that drug shortages often stem from geographic concentration and quality variability, and that standards paired with data-driven risk assessment are key to building supply chain resilience.

Cynthia Challener asked cell-therapy experts about the role of variability in patient-derived starting material. The experts suggested that variability can’t be standardized away and requires risk-based control strategies and clinically representative data to keep autologous manufacturing robust.

Roquette’s Angela Strzelecki argued that patient-centered formulation, 3D-printed dosage forms, and AI-driven development are coming together to make personalized, preventive medicine achievable, as long as the underlying data are well managed.

Contract research organizations are being encouraged to replace manual, disconnected workflows with automation and integrated systems, because efficiency and data integrity define competitive advantage, according to Tim Stroud of Cenevo.

In an interview with PharmTech, Lonza Capsugel’s Jamie Evans and Joe Cobb emphasized that successful sponsor-to-CDMO technology transfer depends on rigorous gap analysis, quality-by-design planning, and strong governance to avoid regulatory and supply delays.

The message from industry experts and regulators is consistent this week: speed and innovation only hold up when they’re backed by rigorous control, data, and collaboration.